GENFIT Reports on Half-Year Liquidity Contract with Crédit Industriel et Commercial

GENFIT, a biopharmaceutical company listed on Nasdaq and Euronext, released its half-year report for the liquidity contract with Crédit Industriel et Commercial. As of June 30, 2025, GENFIT's liquidity account held 201,100 shares and €398,484.67.

Throughout the first half of 2025, GENFIT executed 2,673 buy trades for 1,412,901 shares worth €5,016,550.43, and 1,894 sell trades for 1,419,301 shares, totaling €5,061,074.96. At the start of the contract, resources included 27,911 shares and €769,849.43.

GENFIT, with a focus on liver diseases, operates in Lille, Cambridge, and Zurich. This report reflects their financial positioning amidst their R&D commitments in treating rare liver conditions.